| Entry |
|
|---|
| Name |
Pertuzumab (genetical recombination) (JAN);
Pertuzumab (USAN/INN);
Perjeta (TN)
|
|---|
| Product |
|
|---|
| Activity |
|
|---|
| Remark |
|
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
Genomic biomarker: HER2 [HSA: 2064] positive
 |
|---|
| Structure map |
| Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC13 Pertuzumab
D05446 Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokine receptors
Receptor tyrosine kinase
RTK class I (EGF receptor family)
ERBB2 tyrosine kinase [HSA:2064] [KO:K05083]
Pertuzumab
D05446 Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN)
 |
|---|
| Other DBs |
|
|---|
